Corticosteroid receptor expression and in vivo glucocorticoid sensitivity in multiple sclerosis

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 159-165

  Bechmann, L ^a   Busse, K ^a   Stoppe, M ^a   Cotte, S ^a   Ettrich, B ^a   Then Bergh, F ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Corticosteroid; Glucocorticoid receptor (GR); Hypothalamo pituitary adrenal axis; Mineralocorticoid receptor (MR); Multiple sclerosis (MS)

Indexed keywords

BETA INTERFERON; CORTICOSTEROID RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; DUSP1 PROTEIN, HUMAN; FK 506 BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; TACROLIMUS BINDING PROTEIN 5; TRANSCRIPTION FACTOR; TSC22D3 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DUSP1 GENE; ENZYME ACTIVATION; FEMALE; FKBP5 GENE; GAPDH GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GILZ GENE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NF KB GENE; NR3C1 GENE; NR3C2 GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANALYSIS OF VARIANCE; DUAL SPECIFICITY PHOSPHATASE 1; FEMALE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; TACROLIMUS BINDING PROTEINS; TRANSCRIPTION FACTORS;

EID: 84908556320     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.07.004     Document Type: Article

References (35)

1. Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., Saklatvala J., Clark A.R. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 2006, 203:1883-1889.
2. Ayroldi E., Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009, 23:3649-3658.
3. Boutros T., Chevet E., Metrakos P. Mitogen-activated protein (MAP) Kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 2008, 60:261-310.
4. Chen Y., Burckart G.J., Shah T., Pravica V., Hutchinson I.V. A novel method for monitoring glucocorticoid-induced changes of the glucocorticoid receptor in kidney transplant recipients. Transpl. Immunol. 2009, 20:249-252.
5. Chi H.B., Flavell R.A. Acetylation of MKP-1 and the control of inflammation. Sci. Signal. 2008, 1.
6. Clark A.R. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 2007, 275:79-97.
7. DeRijk R.H., Eskandari F., Sternberg E.M. Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J. Neuroimmunol. 2004, 151:180-188.
8. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control. Clin. Trials 1990, 11:116-128.
9. Eddleston J., Herschbach J., Wagelie-Steffen A.L., Christiansen S.C., Zuraw B.L. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J. Allergy Clin. Immunol. 2007, 119:115-122.
10. Fassbender K., Schmidt R., Mossner R., Kischka U., Kuhnen J., Schwartz A., Hennerici M. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch. Neurol. 1998, 55:66-72.
11. Freeman A.I., Munn H.L., Lyons V., Dammermann A., Seckl J.R., Chapman K.E. Glucocorticoid down-regulation of rat glucocorticoid receptor does not involve differential promoter regulation. J. Endocrinol. 2004, 183:365-374.
12. Gold S.M., Raji A., Huitinga I., Wiedemann K., Schulz K.H., Heesen C. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J. Neuroimmunol. 2005, 165:186-191.
13. Heesen C., Mohr D.C., Huitinga I., Then Bergh F., Gaab J., Otte C., Gold S.M. Stress regulation in multiple sclerosis: current issues and concepts. Mult. Scler. 2007, 13:143-148.
14. Jaaskelainen T., Makkonen H., Palvimo J.J. Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr. Opin. Pharmacol. 2011, 11:326-331.
15. Johansson-Haque K., Palanichamy E., Okret S. Stimulation of MAPK-phosphatase 1 gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP. J. Mol. Endocrinol. 2008, 41:239-249.
16. Kelly M.M., King E.M., Rider C.F., Gwozd C., Holden N.S., Eddleston J., Zuraw B., Leigh R., O'Byrne P.M., Newton R. Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide. Br. J. Pharmacol. 2012, 165:1737-1747.
17. Kümpfel T., Schwan M., Weber F., Holsboer F., Trenkwalder C., Then Bergh F. Hypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosis. Psychoneuroendocrinology 2014, 45:87-95.
18. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 2001, 25:402-408.
20. Miller D.M., Weinstock-Guttman B., Bethoux F., Lee J.C., Beck G., Block V., Durelli L., LaMantia L., Barnes D., Sellebjerg F., Rudick R.A. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult. Scler. 2000, 6:267-273.
21. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST (c)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30.
22. Shipp L.E., Lee J.V., Yu C.Y., Pufall M., Zhang P.L., Scott D.K., Wang J.C. Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. Plos One 2010, 5.
23. Srinivasan M., Janardhanam S. Novel p65 binding glucocorticoid-induced leucine zipper peptide suppresses experimental autoimmune encephalomyelitis. J. Biol. Chem. 2011, 286:44799-44810.
24. Then Bergh F., Grasser A., Trenkwalder C., Backmund H., Holsboer F., Rupprecht R. Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J. Neurol. 1999, 246:292-298.
25. Then Bergh F., Kümpfel T., Trenkwalder C., Rupprecht R., Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999, 53:772-777.
26. Then Bergh F., Kümpfel T., Yassouridis A., Lechner C., Holsboer F., Trenkwalder C. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis. Clin. Endocrinol. (Oxf.) 2007, 66:295-303.
27. U M., Shen L., Oshida T., Miyauchi J., Yamada M., Miyashita T. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 2004, 18:1850-1856.
28. van Winsen L.M.L., Muris D.F.R., Polman C.H., Dijkstra C.D., van den Berg T.K., Uitdehaag B.M.J. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J. Clin. Endocrinol. Metab. 2005, 90:734-740.
29. van Winsen L.M., Polman C.H., Dijkstra C.D., Tilders F.J., Uitdehaag B.M. Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis. Mult. Scler. 2010, 16:500-502.
30. Vermeer H., Hendriks-Stegeman B.I., van Suylekom D., Rijkers G.T., Buul-Offers S.C., Jansen M. An in vitro bioassay to determine individual sensitivity to glucocorticoids: induction of FKBP51 mRNA in peripheral blood mononuclear cells. Mol. Cell. Endocrinol. 2004, 218:49-55.
31. Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C., Yamamoto K.R. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15603-15608.
32. Webster J.I., Sternberg E.M. Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J. Endocrinol. 2004, 181:207-221.
33. Webster J.I., Tonelli L., Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 2002, 20:125-163.
34. Yang J., Fuller P.J. Interactions of the mineralocorticoid receptor-within and without. Mol. Cell. Endocrinol. 2012, 350:196-205.
35. Ysrraelit M.C., Gaitan M.I., Lopez A.S., Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008, 71:1948-1954.